On April 27, 2025, IN8bio, Inc. amended a stock purchase agreement, reducing the exercise price of Series B Warrants from $1.50 to $0.45, and entered into agreements for the exercise of approximately 9.3 million shares, expecting gross proceeds of around $1.9 million.